Concepedia

David L. Halladay

DL

24

Publications

2.1K

Citations

21

H-Index

1984

Active since

Affiliations

Eli Lilly (United States)(Current)

St Vincents Institute of Medical Research

Syracuse University

State University of New York

David L. Halladay is an author at Eli Lilly (United States) specializing in medicine, cell biology, and natural sciences.

Top concepts

Publications per year

1984–2007

24

Publications

24

Catabolic Effects of Continuous Human PTH (1–38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation

Rick L. Cain, David L. Halladay, Xuhao Yang et al. · Endocrinology · 2001 · 426 citations

, , +17

Effects of parathyroid hormone on Wnt signaling pathway in bone

Nalini H. Kulkarni, David L. Halladay, Rebecca R. Miles et al. · Journal of Cellular Biochemistry · 2005 · 218 citations

The Osteoblast-specific Transcription Factor Cbfa1 Contributes to the Expression of Osteoprotegerin, a Potent Inhibitor of Osteoclast Differentiation and Function

Kannan Thirunavukkarasu, David L. Halladay, Rebecca R. Miles et al. · Journal of Biological Chemistry · 2000 · 183 citations · Full text

Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo

Nalini H. Kulkarni, Jude E. Onyia, Qingqiang Zeng et al. · Journal of Bone and Mineral Research · 2006 · 179 citations · Full text

Stimulation of Osteoprotegerin (OPG) Gene Expression by Transforming Growth Factor-β (TGF-β)

Kannan Thirunavukkarasu, Rebecca R. Miles, David L. Halladay et al. · Journal of Biological Chemistry · 2001 · 142 citations · Full text

Rows per page

1–5 of 24